BioArctic AB

BIOA B

SE0010323311

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 07:17:27 15/07/2026 pm IST			5-day change	1st Jan Change
309.80 ^SEK	-1.34%		-3.41%	+0.26%

14/07	Bioarctic: LEADER study shows more than 82 percent of Leqembi patients remained stable or improved	FW
14/07	Leqembi can now be administered at home from the start of treatment in the US	FW

DNB Carnegie raises Bioarctic price target to SEK 363 (342), reiterates Buy

Published on 05/22/2026 at 01:57 pm IST

Finwire - Translated by Marketscreener - See original

Add MarketScreener to your sources

BIOARCTIC AB

-1.34%

DNB Carnegie has raised its price target for Bioarctic to SEK 363 (342) while maintaining its Buy rating.

Add MarketScreener to your sources

Latest news about BioArctic AB

14/07	Bioarctic: LEADER study shows more than 82 percent of Leqembi patients remained stable or improved	FW
14/07	Leqembi can now be administered at home from the start of treatment in the US	FW
14/07	BioArctic, Eisai Win US Approval for Leqembi Iqlik as Starting Dose of Early Alzheimer's Treatment	MT
13/07	BioArctic Says Eisai Presented New Leqembi Data	RE
13/07	Leqembi in an autoinjector showed comparable efficacy and safety to the intravenous formulation	FW
12/07	BioArctic AB and Eisai Present New Clinical Data on Leqembi Subcutaneous Autoinjector Demonstrating Comparable Efficacy and Safety to Iv Formulation in Early Alzheimer's Disease	CI
10/07	Indecap Guide Q30 fell 1.1 percent in June, weighed down by a weaker small-cap market	FW
08/07	Lancelot Sweden fell 0.8% in June, BioArctic slid despite Eli Lilly deal	FW
01/07	Alzecure CEO on the multibillion-dollar deal: 'QuantumCell can get products to market quickly'	FW
30/06	Indecap Guide Q30 rose 3.8 percent in May, Sinch posts strong gains	FW
30/06	Indecap Sverige rose 3.3% in May, steady gains despite mixed earnings picture	FW
30/06	Bioarctic: New Leqembi Data to Be Presented at AAIC 2026	FW
22/06	Hemnet Slips in Stockholm, OMXS30 Index Rises 0.4%	FW
22/06	Down in Stockholm, OMXS30 index slips 0.7%	FW
22/06	Eli Lilly, BioArctic Sign Neurodegeneration Research Deal Worth Up to $800 Million	MT

BioArctic AB is a Swedenâ€‘based biopharmaceutical company specializing in the discovery and development of diseaseâ€‘modifying treatments for neurodegenerative disorders. The Companyâ€™s primary focus is on conditions that affect the central nervous system (CNS), including Alzheimerâ€™s disease, Parkinsonâ€™s disease, and amyotrophic lateral sclerosis (ALS), areas characterized by high unmet medical need and limited effective therapies. BioArctic AB conducts advanced research and development of innovative biological drugs, with a particular emphasis on monoclonal antibodies designed to target the underlying disease mechanisms rather than only alleviating symptoms. The Company combines inâ€‘house scientific expertise with strategic collaborations with global pharmaceutical partners to advance and commercialize its therapeutic candidates worldwide.

Employees

141

Sector

Biotechnology & Medical Research

Calendar

23/07 - Earnings release - Q2 2026

More about the company